In a patient with rheumatoid arthritis on methotrexate and hydroxychloroquine (Plaquenil) who now has lung crackles, dyspnea on exertion, and decreased oxygen saturation, what tests should be performed to evaluate the cause?

Immediate Evaluation: HRCT Chest and Pulmonary Function Tests

In an RA patient on methotrexate and hydroxychloroquine presenting with crackles, dyspnea on exertion, and hypoxemia, you must immediately obtain high-resolution CT (HRCT) chest and pulmonary function tests (PFTs including spirometry, lung volumes, and DLCO) to differentiate between methotrexate-induced pneumonitis, RA-associated interstitial lung disease, and opportunistic infection 1.

Diagnostic Algorithm

First-Line Testing (Obtain Immediately)

1. HRCT Chest (Priority Test)

• HRCT has 95.7% sensitivity for detecting ILD and is superior to standard chest X-ray for evaluating pulmonary complications 1
• Must include inspiratory prone images and supine end-expiratory imaging 1
• Can differentiate between:
  • MTX pneumonitis (typically bilateral ground-glass opacities) 2
  • RA-ILD (various patterns including usual interstitial pneumonia)
  • Infection (consolidations, nodules)

2. Pulmonary Function Tests

• Must include spirometry, lung volumes, and DLCO 1
• Baseline for monitoring if ILD is confirmed
• DLCO particularly sensitive for early interstitial disease

3. Ambulatory Desaturation Testing

• Recommended for SARD-ILD evaluation 1
• Helps quantify functional impairment

Critical Differential Considerations

Methotrexate Pneumonitis (Drug-Induced)

• Can occur at any dose or duration of therapy 3
• Classic presentation: fever, dry nonproductive cough, dyspnea, hypoxemia 3, 4
• Critical pitfall: May present WITHOUT typical interstitial patterns on imaging 5
• Requires immediate MTX discontinuation if suspected 3

Opportunistic Infection (Pneumocystis jirovecii)

• Must be excluded first - potentially fatal if missed 3, 6
• MTX causes immunosuppression increasing PCP risk 3, 6
• Similar presentation to MTX pneumonitis (dyspnea, cough, ground-glass opacities)

RA-Associated ILD

• Occurs in 3-5% of RA patients independent of MTX 1
• Can coexist with or be triggered by MTX 2

Second-Line Invasive Testing (If Diagnosis Unclear)

Bronchoscopy with BAL and Transbronchial Lung Cryobiopsy

• Indicated when: HRCT and clinical picture don't clearly distinguish between infection, MTX pneumonitis, and RA-ILD 5, 2
• BAL fluid analysis:
  • Cultures and special stains for organisms (bacteria, fungi, PCP) 5
  • Cell differential (lymphocytosis suggests drug reaction or ILD)
  • Beta-D-glucan for PCP 6
• Transbronchial lung cryobiopsy provides superior tissue samples compared to standard TBLB 2
  • Can definitively diagnose MTX pneumonitis (interstitial mononuclear infiltration, type II pneumocyte hyperplasia) 5
  • Distinguishes organizing pneumonia patterns 2

Not recommended for routine monitoring: Chest radiography alone (inadequate sensitivity) 1

Management Based on Findings

If MTX Pneumonitis Suspected:

• Immediately discontinue methotrexate 3, 4
• High-dose corticosteroids for severe cases 4, 2
• Most patients recover, but can be life-threatening 4

If Infection Identified:

• Targeted antimicrobial therapy
• For PCP: trimethoprim/sulfamethoxazole plus corticosteroids 6

If RA-ILD Confirmed:

• Continue monitoring per guidelines: PFTs every 3-12 months, ambulatory desaturation every 3-12 months 1
• HRCT when clinically indicated 1
• Consider alternative DMARD therapy

Critical Pitfalls to Avoid

1. Do not assume normal chest X-ray excludes significant disease - HRCT is mandatory 1
2. Do not continue MTX while investigating - if pneumonitis suspected, stop immediately 3
3. Do not skip infection workup - PCP can be fatal and presents identically to MTX pneumonitis 3, 6
4. Do not rely on PFTs alone - they cannot predict acute MTX pneumonitis before symptoms develop 7
5. MTX pneumonitis can occur without typical interstitial patterns - may show consolidations instead 5

The FDA label explicitly warns that pulmonary symptoms require immediate investigation and treatment interruption 3, while the 2023 ACR/CHEST guidelines establish HRCT and PFTs as the standard screening approach for SARD-ILD 1.